Repeated injuries dramatically affect cells of the oligodendrocyte lineage: effects of PDGF and NT-3 in vitro.
In multiple sclerosis, relapses occur and remyelination is incomplete, whereas one demyelinating lesion induced by lysophosphatidyl choline (LPC) in rats is completely remyelinated; this process is accelerated by platelet-derived growth factor (PDGF) (Allamargot et al.: Brain Res 918:28-39,2001) and neurotrophin-3 (NT-3) (Jean et al.: Brain Res 972:110-118,2003). Similarly, oligodendrocyte (OL) progenitors might not be depleted by two to three episodes of toxic demyelination (Penderis et al.: Brain 126:1382-1391,2003); nevertheless this does not allow conclusions about the fate of resident cells (mature OL). As myelinated fibers per OL are constantly decreased in chronic MS plaques (Fressinaud and Jean: J Neurochem 85(suppl):100, 2003), this suggests that OL decreased capability to synthesize new myelin membranes could result from successive relapses, impairing thereby remyelination. Thus, we have determined the consequences of multiple versus unique (Fressinaud and Vallat: J Neurosci Res 38:202-213, 1994) LPC treatments on newborn rat brain pure OL cultures, as well as the putative pro-remyelinating effects of PDGF and of NT-3 in these conditions. Split (0.5. 0(-5) M, 6 h x 4) and multiple (2.10(-5) M, 24 h x 2) LPC doses induced more cell loss than a unique treatment (2 x 10(-5) M, 24 h) and there was no recovery. OL progenitors (A2B5+ cells) and differentiated (CNP+) OL were drastically decreased. Moreover, mature (MBP+) OL disappeared from these cultures, indicating that mature OL are also vulnerable to multiple insults. PDGF, as well as NT-3, induced at least partial recovery, and enhanced OL progenitor proliferation. In cultures treated with either of these growth factors, mature OL represented one-fourth of cells and extended numerous ramified processes and putative myelin balls.
Fressinaud
Catherine
C
Neurology Department, UPRES EA 3143, University Hospital, Angers, France. catherine.fressinaud@med.univ-angers.fr
D000818:Animals; D000831:Animals, Newborn; D016923:Cell Death / Q000187:drug effects / Q000502:physiology; D002454:Cell Differentiation / Q000187:drug effects / Q000502:physiology; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D015536:Down-Regulation / Q000187:drug effects / Q000502:physiology; D004334:Drug Administration Schedule; D018836:Inflammation Mediators / Q000633:toxicity; D008244:Lysophosphatidylcholines / Q000633:toxicity; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000378:metabolism*; D009186:Myelin Sheath / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D009416:Nerve Regeneration / Q000187:drug effects; D020933:Neurotrophin 3 / Q000494:pharmacology*; D009836:Oligodendroglia / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D020127:Recovery of Function / Q000187:drug effects / Q000502:physiology; D013234:Stem Cells / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology
D018836:Inflammation Mediators; D008244:Lysophosphatidylcholines; D020933:Neurotrophin 3; D010982:Platelet-Derived Growth Factor